You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):上半年實現純利6247.8萬港元 同比增加287.7%
格隆匯 08-28 17:03

格隆匯8月28日丨李氏大藥廠(00950.HK)發佈公吿,截至2024年6月30日止六個月,實現收益6.58億港元,同比增加28.5%;毛利為3.51億港元,同比增加23.2%;公司擁有人應占溢利6247.8萬港元,同比增加287.7%;基本每股盈利10.61港仙,每股中期股息2.00港仙。

2024年上半年,集團的收益為較去年同期大增28.5%。此一增長主要源自獲納入最新版《國家基本醫療保險、工傷保險和生育保險藥品目錄》(“國家醫保目錄”)的產品銷情理想,尤其是曲前列尼爾注射液《芮旎爾®》錄得56.8%的可觀增長,而《芮舒延®》及《曲特恪®》則分別增長187.2%及232.1%。此外,藥品集中採購(“藥品集採”)計劃的選定產品(包括那曲肝素鈣注射液《立騰菁®》)銷售額急增近十倍。此等銷售增幅不僅帶動收益錄得可觀增長,亦有助於抵銷回顧期內若干產品銷售額停滯不前的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account